Bard/Endologix
This article was originally published in The Gray Sheet
Executive Summary
Bard passes on its option to acquire minimally invasive abdominal aortic aneurysm device maker Endologix but will remain exclusive distributor for the AAA product in Europe and Australia, the firm announces Dec. 14. The Endologix AAA device "continues to show promise;" however, "we do not believe this opportunity warrants the significant investment required" under the August 1999 option agreement, Bard explains. A fourth quarter charge will be taken in connection with the decision